Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-08-25

AUTHORS

Paul D. Miller, Pierre D. Delmas, Hermann Huss, Katie M. Patel, Ralph C. Schimmer, Silvano Adami, Robert R. Recker

ABSTRACT

The relationship between bisphosphonate-induced bone mineral density (BMD) gains and antifracture efficacy remains to be fully elucidated. Data from two antifracture studies were analyzed. Postmenopausal osteoporotic women received oral (2.5 mg daily, 20 mg intermittent) or intravenous (0.5 mg, 1 mg quarterly) ibandronate. Outcome measures included moving averages plots and logistic regression analyses of the relationship between BMD change and vertebral fracture rate. In moving averages plots, ibandronate-induced BMD gains were consistently associated with decreased fracture rates. In the oral study, total-hip BMD increases at years 2 and 3 and lumbar spine BMD increases at year 3 were associated with 3-year vertebral fracture rate (relative risk reduction [RRR] at year 3 for 1% change from baseline: hip, 7.9% [95% CI 2.1–13.5%, P = 0.0084]; lumbar spine, 4.7% [−0.1% to 9.3%, P = 0.0565]). In the intravenous study, total-hip BMD increases at years 1, 2, and 3 and lumbar spine BMD increases at years 2 and 3 were significantly associated with vertebral fracture rate (RRR at year 3 for 1% change from baseline: hip, 11.6% [7.0–16.0%, P < 0.0001]; lumbar spine, 6.9% [2.9–10.6%, P = 0.0008]). In a pooled analysis, changes in total-hip and lumbar spine BMD were associated with 3-year vertebral fracture risk reduction and explained a substantial proportion of the antifracture effect (23–37% at 2 and 3 years). This analysis suggests that ibandronate-induced BMD gain in postmenopausal osteoporotic women is associated with vertebral fracture risk reduction. More... »

PAGES

305-313

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00223-010-9403-y

DOI

http://dx.doi.org/10.1007/s00223-010-9403-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043493959

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20737140


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diphosphonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hip Joint", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ibandronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lumbar Vertebrae", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Spinal Fractures", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, 80227, Lakewood, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.418833.5", 
          "name": [
            "Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, 80227, Lakewood, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miller", 
        "givenName": "Paul D.", 
        "id": "sg:person.0755056013.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755056013.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM Research Unit 831 and University of Lyon, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.25697.3f", 
          "name": [
            "INSERM Research Unit 831 and University of Lyon, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Delmas", 
        "givenName": "Pierre D.", 
        "id": "sg:person.01155544454.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155544454.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer Vital GmbH, Kaiser-Wilhelm-Allee 1, 51373, Leverkusen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.420044.6", 
          "name": [
            "Bayer Vital GmbH, Kaiser-Wilhelm-Allee 1, 51373, Leverkusen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huss", 
        "givenName": "Hermann", 
        "id": "sg:person.01133530613.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133530613.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche Products, Welwyn Garden City, UK", 
          "id": "http://www.grid.ac/institutes/grid.419227.b", 
          "name": [
            "Roche Products, Welwyn Garden City, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "Katie M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "F. Hoffmann-La Roche, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "F. Hoffmann-La Roche, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schimmer", 
        "givenName": "Ralph C.", 
        "id": "sg:person.015013472234.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015013472234.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Verona, Verona, Italy", 
          "id": "http://www.grid.ac/institutes/grid.5611.3", 
          "name": [
            "University of Verona, Verona, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adami", 
        "givenName": "Silvano", 
        "id": "sg:person.01371164416.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371164416.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Osteoporosis Research Center, Creighton University, Omaha, NE, USA", 
          "id": "http://www.grid.ac/institutes/grid.254748.8", 
          "name": [
            "Osteoporosis Research Center, Creighton University, Omaha, NE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Recker", 
        "givenName": "Robert R.", 
        "id": "sg:person.016325222544.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00198-007-0540-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051377661", 
          "https://doi.org/10.1007/s00198-007-0540-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-007-0543-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048434929", 
          "https://doi.org/10.1007/s00198-007-0543-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-009-0975-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013633075", 
          "https://doi.org/10.1007/s00198-009-0975-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-004-1602-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036604057", 
          "https://doi.org/10.1007/s00198-004-1602-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11914-005-0018-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005249601", 
          "https://doi.org/10.1007/s11914-005-0018-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-08-25", 
    "datePublishedReg": "2010-08-25", 
    "description": "The relationship between bisphosphonate-induced bone mineral density (BMD) gains and antifracture efficacy remains to be fully elucidated. Data from two antifracture studies were analyzed. Postmenopausal osteoporotic women received oral (2.5\u00a0mg daily, 20\u00a0mg intermittent) or intravenous (0.5\u00a0mg, 1\u00a0mg quarterly) ibandronate. Outcome measures included moving averages plots and logistic regression analyses of the relationship between BMD change and vertebral fracture rate. In moving averages plots, ibandronate-induced BMD gains were consistently associated with decreased fracture rates. In the oral study, total-hip BMD increases at years 2 and 3 and lumbar spine BMD increases at year 3 were associated with 3-year vertebral fracture rate (relative risk reduction [RRR] at year 3 for 1% change from baseline: hip, 7.9% [95% CI 2.1\u201313.5%, P\u00a0=\u00a00.0084]; lumbar spine, 4.7% [\u22120.1% to 9.3%, P\u00a0=\u00a00.0565]). In the intravenous study, total-hip BMD increases at years 1, 2, and 3 and lumbar spine BMD increases at years 2 and 3 were significantly associated with vertebral fracture rate (RRR at year 3 for 1% change from baseline: hip, 11.6% [7.0\u201316.0%, P\u00a0<\u00a00.0001]; lumbar spine, 6.9% [2.9\u201310.6%, P\u00a0=\u00a00.0008]). In a pooled analysis, changes in total-hip and lumbar spine BMD were associated with 3-year vertebral fracture risk reduction and explained a substantial proportion of the antifracture effect (23\u201337% at 2 and 3\u00a0years). This analysis suggests that ibandronate-induced BMD gain in postmenopausal osteoporotic women is associated with vertebral fracture risk reduction.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00223-010-9403-y", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1089641", 
        "issn": [
          "0171-967X", 
          "1432-0827"
        ], 
        "name": "Calcified Tissue International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "87"
      }
    ], 
    "keywords": [
      "vertebral fracture rate", 
      "lumbar spine BMD increases", 
      "vertebral fracture risk reduction", 
      "fracture risk reduction", 
      "postmenopausal osteoporotic women", 
      "total hip BMD", 
      "fracture rates", 
      "antifracture efficacy", 
      "BMD gains", 
      "BMD increase", 
      "osteoporotic women", 
      "bone mineral density gains", 
      "spine bone mineral density", 
      "lumbar spine BMD", 
      "bone mineral density", 
      "logistic regression analysis", 
      "risk reduction", 
      "year 2", 
      "antifracture effect", 
      "BMD changes", 
      "pooled analysis", 
      "spine BMD", 
      "intravenous study", 
      "mineral density", 
      "outcome measures", 
      "oral studies", 
      "BMD", 
      "substantial proportion", 
      "regression analysis", 
      "year 3", 
      "women", 
      "efficacy", 
      "year 1", 
      "ibandronate", 
      "hip", 
      "study", 
      "rate", 
      "increase", 
      "average plots", 
      "reduction", 
      "changes", 
      "proportion", 
      "gain", 
      "density gain", 
      "relationship", 
      "analysis", 
      "measures", 
      "effect", 
      "data", 
      "density", 
      "plots"
    ], 
    "name": "Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate", 
    "pagination": "305-313", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043493959"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00223-010-9403-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20737140"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00223-010-9403-y", 
      "https://app.dimensions.ai/details/publication/pub.1043493959"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_518.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00223-010-9403-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00223-010-9403-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00223-010-9403-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00223-010-9403-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00223-010-9403-y'


 

This table displays all metadata directly associated to this object as RDF triples.

255 TRIPLES      21 PREDICATES      97 URIs      84 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00223-010-9403-y schema:about N2062208febb543f1804c7ee3c18e778f
2 N276e8a9dcb57482ebfa6585deca5ea31
3 N2b2a88d8707d4f5186ff645e68bd63f4
4 N327edae2db454211af6d2349243ff5f5
5 N43b8cf4e13d74d85a717534ff2f7200b
6 N535133759a8e4158b77e06083da30d47
7 N547e3ac368654ab58569c0d7bea3e21e
8 N73bf40c78495468ca18ba5bbd79e7750
9 N9298b7bbd1334eaf926c52eee4b45d09
10 N952f405e9a14430aaa63ae1fc48058a6
11 Na31d4b5bdde840aa828a839ec667581d
12 Ncdae4c22fb8c43cd8b7cea6f929c78d6
13 Nd49fd0a03942474ba53d3a80407aaa11
14 Nea653c03ec684064887bcb98d937a602
15 Neadb8403d0d041e7a2a577e68ecc3035
16 Nee8797de62c84eacb0a2161cd60a25e3
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author Nf857e08ab46944328450f2920873a290
20 schema:citation sg:pub.10.1007/s00198-004-1602-9
21 sg:pub.10.1007/s00198-007-0540-8
22 sg:pub.10.1007/s00198-007-0543-5
23 sg:pub.10.1007/s00198-009-0975-1
24 sg:pub.10.1007/s11914-005-0018-6
25 schema:datePublished 2010-08-25
26 schema:datePublishedReg 2010-08-25
27 schema:description The relationship between bisphosphonate-induced bone mineral density (BMD) gains and antifracture efficacy remains to be fully elucidated. Data from two antifracture studies were analyzed. Postmenopausal osteoporotic women received oral (2.5 mg daily, 20 mg intermittent) or intravenous (0.5 mg, 1 mg quarterly) ibandronate. Outcome measures included moving averages plots and logistic regression analyses of the relationship between BMD change and vertebral fracture rate. In moving averages plots, ibandronate-induced BMD gains were consistently associated with decreased fracture rates. In the oral study, total-hip BMD increases at years 2 and 3 and lumbar spine BMD increases at year 3 were associated with 3-year vertebral fracture rate (relative risk reduction [RRR] at year 3 for 1% change from baseline: hip, 7.9% [95% CI 2.1–13.5%, P = 0.0084]; lumbar spine, 4.7% [−0.1% to 9.3%, P = 0.0565]). In the intravenous study, total-hip BMD increases at years 1, 2, and 3 and lumbar spine BMD increases at years 2 and 3 were significantly associated with vertebral fracture rate (RRR at year 3 for 1% change from baseline: hip, 11.6% [7.0–16.0%, P < 0.0001]; lumbar spine, 6.9% [2.9–10.6%, P = 0.0008]). In a pooled analysis, changes in total-hip and lumbar spine BMD were associated with 3-year vertebral fracture risk reduction and explained a substantial proportion of the antifracture effect (23–37% at 2 and 3 years). This analysis suggests that ibandronate-induced BMD gain in postmenopausal osteoporotic women is associated with vertebral fracture risk reduction.
28 schema:genre article
29 schema:isAccessibleForFree false
30 schema:isPartOf N0a6cd8c14c6a49f38e86f3649c7b48f6
31 Nbd0328dd710c41faabd0be900c6a3a9e
32 sg:journal.1089641
33 schema:keywords BMD
34 BMD changes
35 BMD gains
36 BMD increase
37 analysis
38 antifracture effect
39 antifracture efficacy
40 average plots
41 bone mineral density
42 bone mineral density gains
43 changes
44 data
45 density
46 density gain
47 effect
48 efficacy
49 fracture rates
50 fracture risk reduction
51 gain
52 hip
53 ibandronate
54 increase
55 intravenous study
56 logistic regression analysis
57 lumbar spine BMD
58 lumbar spine BMD increases
59 measures
60 mineral density
61 oral studies
62 osteoporotic women
63 outcome measures
64 plots
65 pooled analysis
66 postmenopausal osteoporotic women
67 proportion
68 rate
69 reduction
70 regression analysis
71 relationship
72 risk reduction
73 spine BMD
74 spine bone mineral density
75 study
76 substantial proportion
77 total hip BMD
78 vertebral fracture rate
79 vertebral fracture risk reduction
80 women
81 year 1
82 year 2
83 year 3
84 schema:name Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate
85 schema:pagination 305-313
86 schema:productId N2d1e9c0de09a4d2cbbe36a67df57907d
87 N45a05a23e7c04befbe8c524cdc88fa46
88 Na2b8814decd74effa6f128787f8e7559
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043493959
90 https://doi.org/10.1007/s00223-010-9403-y
91 schema:sdDatePublished 2022-08-04T16:58
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher N23fd231a51dc464ca88820f3067d0419
94 schema:url https://doi.org/10.1007/s00223-010-9403-y
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N07d9ed41ebf64e498a003612fef32330 schema:affiliation grid-institutes:grid.419227.b
99 schema:familyName Patel
100 schema:givenName Katie M.
101 rdf:type schema:Person
102 N09af9200289f416ea2af5f4d85db1d5e rdf:first sg:person.01155544454.25
103 rdf:rest Nca491db10bc441e3a1c96f890c3e2e4c
104 N0a6cd8c14c6a49f38e86f3649c7b48f6 schema:volumeNumber 87
105 rdf:type schema:PublicationVolume
106 N1c4abd4e08d9414595d29c98252b0e78 rdf:first N07d9ed41ebf64e498a003612fef32330
107 rdf:rest N561a943734104728a7264b357a690be9
108 N2062208febb543f1804c7ee3c18e778f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Spinal Fractures
110 rdf:type schema:DefinedTerm
111 N23fd231a51dc464ca88820f3067d0419 schema:name Springer Nature - SN SciGraph project
112 rdf:type schema:Organization
113 N276e8a9dcb57482ebfa6585deca5ea31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Osteoporosis, Postmenopausal
115 rdf:type schema:DefinedTerm
116 N2b2a88d8707d4f5186ff645e68bd63f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Middle Aged
118 rdf:type schema:DefinedTerm
119 N2d1e9c0de09a4d2cbbe36a67df57907d schema:name pubmed_id
120 schema:value 20737140
121 rdf:type schema:PropertyValue
122 N327edae2db454211af6d2349243ff5f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Radiography
124 rdf:type schema:DefinedTerm
125 N43b8cf4e13d74d85a717534ff2f7200b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Bone Density
127 rdf:type schema:DefinedTerm
128 N45a05a23e7c04befbe8c524cdc88fa46 schema:name doi
129 schema:value 10.1007/s00223-010-9403-y
130 rdf:type schema:PropertyValue
131 N535133759a8e4158b77e06083da30d47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Ibandronic Acid
133 rdf:type schema:DefinedTerm
134 N547e3ac368654ab58569c0d7bea3e21e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Aged
136 rdf:type schema:DefinedTerm
137 N561a943734104728a7264b357a690be9 rdf:first sg:person.015013472234.92
138 rdf:rest Na864476f88894cdca6f6adf9902517e9
139 N68ebfdedb6cd47e8b4f237de2f5743a7 rdf:first sg:person.016325222544.69
140 rdf:rest rdf:nil
141 N73bf40c78495468ca18ba5bbd79e7750 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Diphosphonates
143 rdf:type schema:DefinedTerm
144 N9298b7bbd1334eaf926c52eee4b45d09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Lumbar Vertebrae
146 rdf:type schema:DefinedTerm
147 N952f405e9a14430aaa63ae1fc48058a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Hip Joint
149 rdf:type schema:DefinedTerm
150 Na2b8814decd74effa6f128787f8e7559 schema:name dimensions_id
151 schema:value pub.1043493959
152 rdf:type schema:PropertyValue
153 Na31d4b5bdde840aa828a839ec667581d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Injections, Intravenous
155 rdf:type schema:DefinedTerm
156 Na864476f88894cdca6f6adf9902517e9 rdf:first sg:person.01371164416.48
157 rdf:rest N68ebfdedb6cd47e8b4f237de2f5743a7
158 Nbd0328dd710c41faabd0be900c6a3a9e schema:issueNumber 4
159 rdf:type schema:PublicationIssue
160 Nca491db10bc441e3a1c96f890c3e2e4c rdf:first sg:person.01133530613.51
161 rdf:rest N1c4abd4e08d9414595d29c98252b0e78
162 Ncdae4c22fb8c43cd8b7cea6f929c78d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Humans
164 rdf:type schema:DefinedTerm
165 Nd49fd0a03942474ba53d3a80407aaa11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Aged, 80 and over
167 rdf:type schema:DefinedTerm
168 Nea653c03ec684064887bcb98d937a602 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Administration, Oral
170 rdf:type schema:DefinedTerm
171 Neadb8403d0d041e7a2a577e68ecc3035 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Female
173 rdf:type schema:DefinedTerm
174 Nee8797de62c84eacb0a2161cd60a25e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Bone Density Conservation Agents
176 rdf:type schema:DefinedTerm
177 Nf857e08ab46944328450f2920873a290 rdf:first sg:person.0755056013.21
178 rdf:rest N09af9200289f416ea2af5f4d85db1d5e
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
183 schema:name Clinical Sciences
184 rdf:type schema:DefinedTerm
185 sg:journal.1089641 schema:issn 0171-967X
186 1432-0827
187 schema:name Calcified Tissue International
188 schema:publisher Springer Nature
189 rdf:type schema:Periodical
190 sg:person.01133530613.51 schema:affiliation grid-institutes:grid.420044.6
191 schema:familyName Huss
192 schema:givenName Hermann
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133530613.51
194 rdf:type schema:Person
195 sg:person.01155544454.25 schema:affiliation grid-institutes:grid.25697.3f
196 schema:familyName Delmas
197 schema:givenName Pierre D.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155544454.25
199 rdf:type schema:Person
200 sg:person.01371164416.48 schema:affiliation grid-institutes:grid.5611.3
201 schema:familyName Adami
202 schema:givenName Silvano
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371164416.48
204 rdf:type schema:Person
205 sg:person.015013472234.92 schema:affiliation grid-institutes:grid.417570.0
206 schema:familyName Schimmer
207 schema:givenName Ralph C.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015013472234.92
209 rdf:type schema:Person
210 sg:person.016325222544.69 schema:affiliation grid-institutes:grid.254748.8
211 schema:familyName Recker
212 schema:givenName Robert R.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69
214 rdf:type schema:Person
215 sg:person.0755056013.21 schema:affiliation grid-institutes:grid.418833.5
216 schema:familyName Miller
217 schema:givenName Paul D.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755056013.21
219 rdf:type schema:Person
220 sg:pub.10.1007/s00198-004-1602-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036604057
221 https://doi.org/10.1007/s00198-004-1602-9
222 rdf:type schema:CreativeWork
223 sg:pub.10.1007/s00198-007-0540-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051377661
224 https://doi.org/10.1007/s00198-007-0540-8
225 rdf:type schema:CreativeWork
226 sg:pub.10.1007/s00198-007-0543-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048434929
227 https://doi.org/10.1007/s00198-007-0543-5
228 rdf:type schema:CreativeWork
229 sg:pub.10.1007/s00198-009-0975-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013633075
230 https://doi.org/10.1007/s00198-009-0975-1
231 rdf:type schema:CreativeWork
232 sg:pub.10.1007/s11914-005-0018-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005249601
233 https://doi.org/10.1007/s11914-005-0018-6
234 rdf:type schema:CreativeWork
235 grid-institutes:grid.254748.8 schema:alternateName Osteoporosis Research Center, Creighton University, Omaha, NE, USA
236 schema:name Osteoporosis Research Center, Creighton University, Omaha, NE, USA
237 rdf:type schema:Organization
238 grid-institutes:grid.25697.3f schema:alternateName INSERM Research Unit 831 and University of Lyon, Lyon, France
239 schema:name INSERM Research Unit 831 and University of Lyon, Lyon, France
240 rdf:type schema:Organization
241 grid-institutes:grid.417570.0 schema:alternateName F. Hoffmann-La Roche, Basel, Switzerland
242 schema:name F. Hoffmann-La Roche, Basel, Switzerland
243 rdf:type schema:Organization
244 grid-institutes:grid.418833.5 schema:alternateName Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, 80227, Lakewood, CO, USA
245 schema:name Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, 80227, Lakewood, CO, USA
246 rdf:type schema:Organization
247 grid-institutes:grid.419227.b schema:alternateName Roche Products, Welwyn Garden City, UK
248 schema:name Roche Products, Welwyn Garden City, UK
249 rdf:type schema:Organization
250 grid-institutes:grid.420044.6 schema:alternateName Bayer Vital GmbH, Kaiser-Wilhelm-Allee 1, 51373, Leverkusen, Germany
251 schema:name Bayer Vital GmbH, Kaiser-Wilhelm-Allee 1, 51373, Leverkusen, Germany
252 rdf:type schema:Organization
253 grid-institutes:grid.5611.3 schema:alternateName University of Verona, Verona, Italy
254 schema:name University of Verona, Verona, Italy
255 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...